Outlook Therapeutics Inc (NASDAQ: OTLK) has appointed Alicia Tozier as its new Marketing and Market Access and Senior Vice President.
According to its chief commercial officer, Jeff Evanson, the company is happy to expand its commercial expertise by adding Tozier to its team. Tozier proved her capabilities when she led the company in introducing some AMD therapies. For this reason, she is the right person to lead the potential launch of the ONS-5010 ophthalmic bevacizumab if the U.S Food and Drug Administration (FDA) gives its approval.
Tozier’s work experience
Tozier has experience in nine areas of ophthalmologic diseases. Moreover, she launched products to treat eyes diseases, including digital therapeutics, pharmaceuticals, and medical devices. Tozier has also worked for prominent companies like Baxters, Astellas, and Genentech.
Evanson adds that Tozier’s expertise is vital as the company intends to release ONS-5010. She could also be instrumental as the company contemplates developing a pre-filled syringe for the drug. Tozier’s leadership will also come in handy as Outlook Therapeutics goes into other projects.
Tozier’s role will be to ensure that the launch of ONS-5010 is successful. Her job will include creating a global marketing strategy to increase customer awareness of the launch. Furthermore, Tozier will work directly under Evanson.
Tozier states that she is excited to use her experience to benefit the company. She will leverage her experience in launching therapies, extensive network, and experience in wet AMD and retina. She adds that ONS-5010 can become a preferred therapy for doctors and physicians.
Outlook Therapeutics is making plans ahead of the ONS-5010 approval
Outlook Therapeutics plans on submitting BLA (Biologics License Application) to the FDA for its drug in Q1 2022. While the company awaits approval, it has already made plans to manufacture the drug with Aji Biopharma Services and FUJIFILM Diosynth Biotechnologies. It is also planning community engagement, sales, and board outreach programs.
The company is discussing with the retina community and payors how the launch will benefit them. Meanwhile, it is drawing up registration documents to facilitate the approval of ONS-5010 in Europe. The company hopes to submit these documents by Q4 2022.
The company hopes that ONS-5010 becomes the only bevacizumab for retinal conditions that the FDA approves in Japan, Europe, the U.K, and the U.S.
